JP2006502195A5 - - Google Patents

Download PDF

Info

Publication number
JP2006502195A5
JP2006502195A5 JP2004538994A JP2004538994A JP2006502195A5 JP 2006502195 A5 JP2006502195 A5 JP 2006502195A5 JP 2004538994 A JP2004538994 A JP 2004538994A JP 2004538994 A JP2004538994 A JP 2004538994A JP 2006502195 A5 JP2006502195 A5 JP 2006502195A5
Authority
JP
Japan
Prior art keywords
pyridylmethyl
vitamin
formula
compound
phthalazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004538994A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006502195A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/010578 external-priority patent/WO2004028542A1/en
Publication of JP2006502195A publication Critical patent/JP2006502195A/ja
Publication of JP2006502195A5 publication Critical patent/JP2006502195A5/ja
Pending legal-status Critical Current

Links

JP2004538994A 2002-09-24 2003-09-23 骨髄異形成症候群の処置用医薬の製造のための4−ピリジルメチル−フタラジン誘導体の使用 Pending JP2006502195A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41317602P 2002-09-24 2002-09-24
PCT/EP2003/010578 WO2004028542A1 (en) 2002-09-24 2003-09-23 Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes

Publications (2)

Publication Number Publication Date
JP2006502195A JP2006502195A (ja) 2006-01-19
JP2006502195A5 true JP2006502195A5 (https=) 2006-11-09

Family

ID=32043216

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004538994A Pending JP2006502195A (ja) 2002-09-24 2003-09-23 骨髄異形成症候群の処置用医薬の製造のための4−ピリジルメチル−フタラジン誘導体の使用

Country Status (22)

Country Link
US (1) US20060128716A1 (https=)
EP (1) EP1545534B1 (https=)
JP (1) JP2006502195A (https=)
KR (1) KR20050074450A (https=)
CN (1) CN100372535C (https=)
AT (1) ATE359789T1 (https=)
AU (1) AU2003299065B2 (https=)
BR (1) BR0314647A (https=)
CA (1) CA2499738A1 (https=)
CR (1) CR7754A (https=)
DE (1) DE60313344T2 (https=)
EC (1) ECSP055700A (https=)
ES (1) ES2285251T3 (https=)
HR (1) HRP20050281A2 (https=)
MX (1) MXPA05003161A (https=)
NO (1) NO20051936L (https=)
PL (1) PL374696A1 (https=)
PT (1) PT1545534E (https=)
RS (1) RS20050228A (https=)
RU (1) RU2353364C2 (https=)
WO (1) WO2004028542A1 (https=)
ZA (1) ZA200502212B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875451B2 (en) * 1997-10-15 2005-04-05 Polarx Biopharmaceuticals Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
CN101277939A (zh) 2005-09-09 2008-10-01 布里斯托尔-迈尔斯斯奎布公司 无环ikur抑制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7132458B2 (en) * 1994-08-10 2006-11-07 Chemaphor Inc. Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
RU2136308C1 (ru) * 1994-11-16 1999-09-10 Жемчугов Владислав Евгеньевич Стимулятор роста костно-мозговых клеток человека
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CN1660840A (zh) * 1999-03-30 2005-08-31 诺瓦提斯公司 治疗炎性疾病的酞嗪衍生物
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
EP1248625A2 (en) * 1999-12-06 2002-10-16 Rhode Island Hospital Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors

Similar Documents

Publication Publication Date Title
JP2005533748A5 (https=)
EP0622076B1 (en) Inhibitor for restenosis after percutaneous coronary arterioplasty
JP2001518517A5 (https=)
RU2375058C2 (ru) Комбинации, включающие эпотилоны, и их фармацевтическое применение
JP2005501825A5 (https=)
AU2002328921A1 (en) Combinations comprising epothilones and pharmaceutical uses thereof
KR100812693B1 (ko) 항종양 효과 증강제 및 항종양제
JP2006502195A5 (https=)
US6881751B2 (en) Medicament containing platinum complex compounds and the use thereof
EP1545534B1 (en) Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes
AU2002251763B2 (en) Method for treating cancer
JP2003535874A (ja) 置換アクリロイルジスタマイシン誘導体、タキサン類及び/又は代謝拮抗剤を含む腫瘍に対する併用療法
AU2002251763A1 (en) Method for treating cancer
JP2006503874A5 (https=)
JP2002518467A5 (https=)
JP2006507319A5 (https=)
JP2022519930A5 (https=)
JP2006503874A (ja) Ammの処置
AU2008203233A1 (en) Combinations comprising epothilones and pharmaceutical uses thereof
WO2004056367A1 (en) Treatment of von hippel lindau disease
WO2006105317A2 (en) Antitumorigemic drug combination comprising a vegf-inhibitor and a thrombospondin-1 peptidomimetic